Medifron DBT Co. Ltd
Hyper Corporation Inc., a clinical stage biopharmaceutical company, focuses on the development of Alzheimer's disease (AD) and neuropathic pain treatments, and AD diagnostics. Its products under development include TRPV1 Antagonist and TRPV1 Agonist for neuropathic pain; and anti-oligomerization of beta-amyloid, receptor for advanced glycation endproduct modulator, and early diagnosis kits for AD… Read more
Medifron DBT Co. Ltd (065650) - Net Assets
Latest net assets as of September 2025: ₩27.00 Billion KRW
Based on the latest financial reports, Medifron DBT Co. Ltd (065650) has net assets worth ₩27.00 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩113.62 Billion) and total liabilities (₩86.61 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩27.00 Billion |
| % of Total Assets | 23.77% |
| Annual Growth Rate | -3.49% |
| 5-Year Change | -37.22% |
| 10-Year Change | -26.51% |
| Growth Volatility | 32.28 |
Medifron DBT Co. Ltd - Net Assets Trend (2014–2024)
This chart illustrates how Medifron DBT Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Medifron DBT Co. Ltd (2014–2024)
The table below shows the annual net assets of Medifron DBT Co. Ltd from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩17.49 Billion | -52.60% |
| 2023-12-31 | ₩36.89 Billion | +18.66% |
| 2022-12-31 | ₩31.09 Billion | -26.48% |
| 2021-12-31 | ₩42.29 Billion | +51.82% |
| 2020-12-31 | ₩27.86 Billion | +57.47% |
| 2019-12-31 | ₩17.69 Billion | -7.85% |
| 2018-12-31 | ₩19.20 Billion | -22.44% |
| 2017-12-31 | ₩24.75 Billion | -3.22% |
| 2016-12-31 | ₩25.57 Billion | +7.46% |
| 2015-12-31 | ₩23.80 Billion | -4.58% |
| 2014-12-31 | ₩24.94 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Medifron DBT Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 12944001090000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩53.34 Billion | 305.00% |
| Other Components | ₩106.83 Billion | 610.85% |
| Total Equity | ₩17.49 Billion | 100.00% |
Medifron DBT Co. Ltd Competitors by Market Cap
The table below lists competitors of Medifron DBT Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Iktinos Hellas S.A. Greek Marble Industry Technical and Touristic Company
AT:IKTIN
|
$11.65 Million |
|
Becker Milk Co Ltd Cl B Nv Spec (BEK-B.TO
TO:BEK-B
|
$11.65 Million |
|
IT Link
PA:ALITL
|
$11.65 Million |
|
LiqTech International Inc
NASDAQ:LIQT
|
$11.66 Million |
|
Pungkang Co. Ltd
KQ:093380
|
$11.65 Million |
|
TRC Construction Public Company Limited
BK:TRC
|
$11.65 Million |
|
Masterkool International Public Company Limited
BK:KOOL
|
$11.64 Million |
|
MClean Technologies Bhd
KLSE:0167
|
$11.63 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Medifron DBT Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 36,892,838,020 to 17,489,044,000, a change of -19,403,794,020 (-52.6%).
- Net loss of 80,357,139,610 reduced equity.
- Share repurchases of 42,003,999,650 reduced equity.
- New share issuances of 42,003,999,650 increased equity.
- Other factors increased equity by 60,953,345,590.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-80.36 Billion | -459.47% |
| Share Repurchases | ₩42.00 Billion | -240.17% |
| Share Issuances | ₩42.00 Billion | +240.17% |
| Other Changes | ₩60.95 Billion | +348.52% |
| Total Change | ₩- | -52.60% |
Book Value vs Market Value Analysis
This analysis compares Medifron DBT Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.55x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.17x to 1.55x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩934.42 | ₩2030.00 | x |
| 2017-12-31 | ₩840.71 | ₩2030.00 | x |
| 2018-12-31 | ₩652.07 | ₩2030.00 | x |
| 2019-12-31 | ₩600.90 | ₩2030.00 | x |
| 2020-12-31 | ₩748.83 | ₩2030.00 | x |
| 2021-12-31 | ₩7756.87 | ₩2030.00 | x |
| 2022-12-31 | ₩660.90 | ₩2030.00 | x |
| 2023-12-31 | ₩5704.02 | ₩2030.00 | x |
| 2024-12-31 | ₩1313.59 | ₩2030.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Medifron DBT Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -459.47%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -137.45%
- • Asset Turnover: 0.97x
- • Equity Multiplier: 3.45x
- Recent ROE (-459.47%) is below the historical average (-61.29%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -34.09% | -157.24% | 0.20x | 1.06x | ₩-11.00 Billion |
| 2015 | -7.18% | -20.79% | 0.27x | 1.30x | ₩-4.09 Billion |
| 2016 | -15.49% | -30.25% | 0.47x | 1.09x | ₩-6.52 Billion |
| 2017 | -46.27% | -54.77% | 0.80x | 1.06x | ₩-13.93 Billion |
| 2018 | -28.98% | -27.97% | 0.92x | 1.12x | ₩-7.48 Billion |
| 2019 | -10.06% | -10.22% | 0.89x | 1.10x | ₩-3.55 Billion |
| 2020 | -12.64% | -11.21% | 0.67x | 1.70x | ₩-6.31 Billion |
| 2021 | -15.98% | -13.72% | 1.00x | 1.16x | ₩-10.99 Billion |
| 2022 | -38.68% | -26.55% | 0.81x | 1.79x | ₩-15.13 Billion |
| 2023 | -5.31% | -4.57% | 0.77x | 1.51x | ₩-5.65 Billion |
| 2024 | -459.47% | -137.45% | 0.97x | 3.45x | ₩-82.11 Billion |
Industry Comparison
This section compares Medifron DBT Co. Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Medifron DBT Co. Ltd (065650) | ₩27.00 Billion | -34.09% | 3.21x | $11.65 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |